Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.
Albertini
M R
MR
Department of Human Oncology, University of Wisconsin, Madison 53792.
Hank
J A
JA
Sondel
P M
PM
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000502:physiology; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D015375:Receptors, Interleukin-2